Treatment of systemic lupus erythematosus in 2006

Joint Bone Spine

Volumn 73, Issue 6, 2006, Pages 591-598

  Sibilia, Jean ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Biotherapies; Hydroxychloroquine; Immunotherapy; Rituximab; Systemic lupus erythematosus; TNF antagonists

Indexed keywords

ABATACEPT; ABETIMUS; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; BELILUMAB; BETA INTERFERON; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYCLOPHOSPHAMIDE; EPRATUZUMAB; ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LEVONORGESTREL; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PLACEBO; PRASTERONE; RITUXIMAB; TACROLIMUS; TAMOXIFEN; TUMOR NECROSIS FACTOR ANTIBODY; VACCINE; IMMUNOSUPPRESSIVE AGENT;

ACNE; ANTIPHOSPHOLIPID SYNDROME; ATHEROMA; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IMMUNOREGULATION; IMMUNOTHERAPY; INTRAUTERINE CONTRACEPTIVE DEVICE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UNSPECIFIED SIDE EFFECT; REVIEW; RHEUMATOLOGY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATOLOGY;

EID: 33845483348     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.09.003     Document Type: Short Survey

References (85)

1. Costenbader K.H., Kim D.J., Peerzada J., Lockman S., Nobles-Knight D., Petri M., et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004;50:849-57. Freemer MM, King TE, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann. Rheum. Dis. 65 (2006) 581-584
2. Fust G., Arason G.J., Kramer J., Szalai C., Duba J., Yang Y., et al. Genetic basis of tobacco smoking: strong association of a specific major histocompatibility complex haplotype on chromosome 6 with smoking behavior. Int. Immunol. 16 (2004) 1507-1514
3. Coban C., Ishii K.J., Kawai T., Hemmi H., Sato S., Uematsu S., et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201 (2005) 19-25
4. Wu X., and Peng S.L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54 (2006) 336-342
5. Costedoat-Chalumeau N., Amoura Z., Duhaut P., Huong du L.T., Sebbough D., Wechsler B., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48 (2003) 3207-3211
6. Tett S.E., Cutler D.J., Beck C., and Day R.O. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis-a prospective, dose ranging study. J. Rheumatol. 27 (2000) 1656-1660
7. Flanc R.S., Roberts M.A., Strippoli G.F., Chadban S.J., Kerr P.G., and Atkins R.C. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am. J. Kidney Dis. 43 (2004) 197-208
8. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., Garrido Ed Ede R., Danieli M.G., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46 (2002) 2121-2131
9. Grimaldi C.M., Jeganathan V., and Diamond B. Hormonal regulation of B cell development: 17beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J. Immunol. 176 (2006) 2703-2710
10. Buyon J.P., Petri M.A., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142 (2005) 953-962
11. Sanchez-Guerrero J., Uribe A.G., Jimenez-Santana L., Mestanza-Peralta M., Lara-Reyes P., Seuc A.H., et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med. 353 (2005) 2539-2549
12. Petri M.A., Lahita R.G., Van Vollenhoven R.F., Merrill J.T., Schiff M., Ginzler E.M., et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 46 (2002) 1820-1829
13. van Vollenhoven R.F., Engleman E.G., and McGuire J.L. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. 38 (1995) 1826-1831
14. Van Vollenhoven R.F., Engleman E.G., and McGuire J.L. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. 37 (1994) 1305-1310
15. Petri M.A., Mease P.J., Merrill J.T., Lahita R.G., Iannini M.J., Yocum D.E., et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 2858-2868
16. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343 (2000) 1156-1162
17. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353 (2005) 2219-2228
18. Ong L.M., Hooi L.S., Lim T.O., Goh B.L., Ahmad G., Ghazalli R., et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrol. 10 (2005) 504-510
19. Hu W., Liu Z., Chen H., Tang Z., Wang Q., Shen K., et al. Mycophenolate mofetil vs. cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. (Engl.) 115 (2002) 705-709
20. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350 (2004) 971-980
21. Chan T.M., Tse K.C., Tang C.S., Mok M.Y., and Li F.K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16 (2005) 1076-1084
22. Mok C.C., Tong K.H., To C.H., Siu Y.P., and Au T.C. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 68 (2005) 813-817
23. Davidson A., Diamond B., Wofsy D., and Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus 14 (2005) 197-203
24. Sfikakis P.P., Boletis J.N., and Tsokos G.C. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. 17 (2005) 550-557
25. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64 (2005) 913-920
26. Anolik J.H., Campbell D., Felgar R.E., Young F., Sany I., Rosenblatt J., et al. The relation ship of FcγR IIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48 (2003) 455-459
27. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3580-3590
28. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52 (2005) 501-513
29. Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatol. 44 (2005) 176-182
30. Tahir H., Rohrer J., Bhatia A., Wegener W.A., and Isenberg D.A. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatol. 44 (2005) 561-562
31. Faderl S., Thomas D.A., O'Brien S., Garcia-Manero G., Kantarjian H.M., Giles F.J., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101 (2003) 3413-3415
32. Carnahan J., Wang P., Kendall R., Chen C., Hu S., Boone T., et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. 9 (2003) 39825-39905
33. Dörner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8 (2006) R74
34. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48 (2003) 3253-3265
35. Furie R.A., Cash J.M., Cronin M.E., Katz R.S., Weisman M.H., and Aranow C. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28 (2001) 257-265
36. Alarcon-Segovia D., Tumlin J.A., Furie R.A., McKay J.D., Cardiel M.H., Strand V., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48 (2003) 442-454
37. Strand V., Aranow C., Cardiel M.H., Alarcon-Segovia D., Furie R., Sherrer Y., et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 12 (2003) 677-686
38. Wallace D.J. Apheresis for lupus erythematosus: state of the art. Lupus 10 (2001) 193-196
39. Couzin J. Drug development. Lupus drug company asks FDA for second chance. Science 307 (2005) 835
40. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100 (2003) 2610-2615
41. Kirou K.A., Lee C., George S., Louca K., Papagiannis I.G., Peterson M.G., et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50 (2004) 3958-3967
42. Gottenberg J.E., Cagnard N., Lucchesi C., Letourneur F., Mistou S., Lazure T., et al. Activation of interferon pathways and plasmacytoid dendritic cell recruitment in target organs from patients with primary Sjögren's syndrome. Proc. Natl. Acad. Sci. USA 108 (2006) 2770-2775
43. Kirou K.A., Lee C., George S., Louca K., Peterson M.G.E., and Crow M.K. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52 (2005) 1491-1503
44. Hueber W., Zeng D., Strober S., and Utz P.J. Interferon-α-inducible proteins are novel autoantigens in murine lupus. Arthritis Rheum. 50 (2004) 3239-3249
45. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., and Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115 (2005) 407-417
46. Li J., Liu Y., Xie C., Zhu J., Kreska D., Morel L., et al. Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum. 52 (2005) 3063-3072
47. Schwarting A., Paul K., Tschirner S., Menke J., Hansen T., Brenner W., et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J. Am. Soc. Nephrol. 16 (2005) 3264-3272
48. Hron J.D., and Peng S.L. Type I IFN protects against murine lupus. J. Immunol. 173 (2004) 2134-2142
49. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197 (2003) 777-788
50. Medarex. Human monoclonal antibodies to IFN-α for the treatment of autoimmune diseases. Expert Opin Ther Patents 16 (2006) 221-229
51. Eilat E., Dayan M., Zinger H., and Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 98 (2001) 1148-1153
52. Monneaux F., Hoebeke J., Sordet C., Nonn C., Briand J.P., Maillere B., et al. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J. Immunol. 175 (2005) 5839-5847
53. Suen J.L., Chuang Y.H., Tsai B.Y., Yau P.M., and Chiang B.L. Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum. 50 (2004) 3250-3259
54. Sela U., Mauermann N., Hershkoviz R., Zinger H., Dayan M., Cahalon L., et al. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function. J. Immunol. 175 (2005) 7255-7263
55. Hahn B.H., Singh R.P., La Cava A., and Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J. Immunol. 175 (2005) 7728-7737
56. Sharabi A., Haviv A., Zinger H., Dayan M., and Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin. Immunol. 119 (2006) 146-155
57. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
58. Amital H., Heilweil M., Ulmansky R., Szafer F., Bar-Tana R., Morel L., et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J. Immunol. 175 (2005) 5516-5523
59. Goulvestre C., Chereau C., Nicco C., Mouthon L., Weill B., and Batteux F. A mimic of p21WAF1/CIP1 ameliorates murine lupus. J. Immunol. 175 (2005) 6959-6967
60. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50 (2004) 3161-3169
61. Gerl V., Hostmann B., Johnen C., Waka A., Gerl M., Schumann F., et al. The intracellular 52-kDa Ro/SSA autoantigen in keratinocytes is up-regulated by tumor necrosis factor alpha via tumor necrosis factor receptor I. Arthritis Rheum. 52 (2005) 531-538
62. Wang Y., Hu Q., Madri J.A., Rollins S.A., Chodera A., and Matis L.A. Amelioration of lupus like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93 (1996) 8563-8568
63. Bao L., Osawe I., Haas M., and Quigg R.J. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J. Immunol. 175 (2005) 1947-1955
64. Bao L., Osawe I., Puri T., Lambris J.D., Haas M., and Quigg R.J. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur. J. Immunol. 35 (2005) 2496-2506
65. Bao L., Haas M., Boackle S.A., Kraus D.M., Cunningham P.N., Park P., et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/Lpr mice. J. Immunol. 168 (2002) 3601-3607
66. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., et al. Complement C3 activation is required for anti-phospholipid antibody-induced fetal loss. J. Exp. Med. 178 (2002) 166-176
67. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., and Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287 (2000) 498-501
68. Holers V.M. The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107 (2003) 140-151
69. Kolln J., Spillner E., Andra J., Klensang K., and Bredehorst R. Complement inactivation by recombinant human C3 derivatives. J. Immunol. 173 (2004) 5540-5545
70. Girardi G., Redecha P., and Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10 (2004) 1222-1226
71. McGaha T.L., Sorrentino B., and Ravetch J.V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307 (2005) 590-593
72. Barber D.F., Bartolome A., Hernandez C., Flores J.M., Redondo C., Fernandez-Arias C., et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11 (2005) 933-935
73. Barber D.F., Bartolome A., Hernandez C., Flores J.M., Fernandez-Arias C., Rodriguez-Borlado L., et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J. Immunol. 176 (2006) 589-593
74. Sadanaga A., Nakashima H., Masutani K., Miyake K., Shimizu S., Igawa T., et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum. 52 (2005) 3987-3996
75. Rodriguez W., Mold C., Marnell L.L., Hutt J., Silverman G.J., Tran D., et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum. 54 (2006) 325-335
76. Xu L., Zhang L., Yi Y., Kang H.K., and Datta S.K. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat. Med. 10 (2004) 411-415
77. Greeneltch K.M., Kelly-Welch A.E., Shi Y., and Keegan A.D. Chronic morphine treatment promotes specific Th2 cytokine production by murine T cells in vitro via a Fas/Fas ligand-dependent mechanism. J. Immunol. 175 (2005) 4999-5005
78. Burt R.K., Traynor A., Statkute L., Barr W.G., Rosa R., Schroeder J., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295 (2006) 527-535
79. De Kleer I., Vastert B., Klein M., Teklenburg G., Arkesteijn G., Yung G.P., et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107 (2006) 1696-1702
80. Haque S., and Bruce I.N. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2 (2005) 423-430
81. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349 (2003) 2399-2406
82. Jury E.C., and Ehrenstein M.R. Statins: immunomodulators for autoimmune rheumatic disease?. Lupus 14 (2005) 192-196
83. Ohlenschlaeger T., Garred P., Madsen H.O., and Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N. Engl. J. Med. 351 (2004) 260-267
84. Mok M.Y., Jack D.L., Lau C.S., Fong D.Y., Turner M.W., Isenberg D.A., et al. Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 13 (2004) 522-528
85. Summerfield J.A. Clinical potential of mannose-binding lectin-replacement therapy. Biochem. Soc. Trans. 31 (2003) 770-773